Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.54 |
| ▸ | MEN1 | O00255 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CHKA | P35790 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | LIPE | Q05469 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | SPR | P35270 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15451912 | 0.95 | ALDH1A1 (0.56) | ALDH1A1MEN1KMT2ATP53CA2 | |
| SCHEMBL13450558 | 0.93 | ALDH1A1 (0.61) | ALDH1A1MEN1KMT2ATP53CA2 | |
| SCHEMBL17177148 | 0.91 | ALDH1A1 (0.50) | ALDH1A1MEN1KMT2ATP53CA2 | |
| SCHEMBL4815774 | 0.86 | ALDH1A1 (0.52) | ALDH1A1MEN1KMT2ATP53CA2 | |
| SCHEMBL4815766 | 0.86 | ALDH1A1 (0.52) | ALDH1A1MEN1KMT2ATP53CA2 | |
| SCHEMBL18855601 | 0.85 | ALDH1A1 (0.56) | ALDH1A1MEN1KMT2ATP53CA2 | |
| SCHEMBL872152 | 0.79 | ALDH1A1 (0.81) | ALDH1A1MEN1KMT2ATP53CA2 | |
| SCHEMBL23817652 | 0.77 | EPHX2 (0.47) | ALDH1A1MEN1KMT2ACYP2C9CYP2C19 | |
| SCHEMBL18563742 | 0.77 | ALDH1A1 (0.52) | ALDH1A1MEN1KMT2ATP53CA2 | |
| SCHEMBL3948691 | 0.76 | ALDH1A1 (0.88) | ALDH1A1MEN1KMT2ATP53CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10744155-B2 | Inhibitors of ADAMTS4 or ADAMTS5 for use in preventing or treating cardiac remodeling and chronic heart failure | UNIVERSITETET I OSLO (NO) | 2020-08-18 | — | — | US | disclosed |
| US-20190282606-A1 | INHIBITORS OF ADAMTS4 OR ADAMTS5 FOR USE IN PREVENTING OR TREATING CARDIAC REMODELING AND CHRONIC HEART FAILURE | UNIVERSITETET I OSLO (NO) | 2019-09-19 | — | — | US | disclosed |
| US-20160158271-A1 | INHIBITORS OF ADAMTS4 OR ADAMTS5 FOR USE IN PREVENTING OR TREATING CARDIAC REMODELING AND CHRONIC HEART FAILURE | UNIVERSITETET I OSLO (NO) | 2016-06-09 | — | — | US | disclosed |
| US-20160158271-A1 | INHIBITORS OF ADAMTS4 OR ADAMTS5 FOR USE IN PREVENTING OR TREATING CARDIAC REMODELING AND CHRONIC HEART FAILURE | UNIVERSITETET I OSLO (NO) | 2016-06-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190282606-A1 | INHIBITORS OF ADAMTS4 OR ADAMTS5 FOR USE IN PREVENTING OR TREATING CARDIAC REMODELING AND CHRONIC HEART FAILURE | ADAMTS5, ADAMTS4, ADAMTS1 | ALDH1A1 2311/4885MEN1 3006/4885KMT2A 2260/4885 |
| US-20160158271-A1 | INHIBITORS OF ADAMTS4 OR ADAMTS5 FOR USE IN PREVENTING OR TREATING CARDIAC REMODELING AND CHRONIC HEART FAILURE | ADAMTS5, ADAMTS4, ADAMTS1 | ALDH1A1 2311/4885MEN1 3006/4885KMT2A 2260/4885 |
| US-10744155-B2 | Inhibitors of ADAMTS4 or ADAMTS5 for use in preventing or treating cardiac remodeling and chronic heart failure | ADAMTS5, ADAMTS4, ADAMTS1 | ALDH1A1 2311/4885MEN1 3006/4885KMT2A 2260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.